We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Laboratory Corp. of America Holdings (LH - Free Report) is a leading independent clinical laboratory, whose offerings include a broad range of routine tests (including blood chemistry analysis, urinalyses, blood cell count, thyroid test, Pap tests and HIV tests) as well as specialty testing operations or esoteric testing.
Currently, LabCorp has a Zacks Rank #4(Sell) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at $2.19 per share over the last 30 days. LabCorp’s first quarter adjusted earnings per share of $2.22, up 8% year over year has surpassed this estimate by 1.4%.
Laboratory Corporation of America Holdings Price and EPS Surprise
Sales: LabCorp posted sales of $2,408.1 million in the reported quarter, which has marginally missed the Zacks Consensus Estimate for sales of $2,411.0 million.
Key Stats: Revenues from LabCorp Diagnostics segment increased 8.0% year over year to $1.72 billion in the first quarter, with total volume growth of 4.3%. However, revenues from Covance Drug Development segment declined by 1.8% year over year to $690.3 million because of sluggish revenue conversion and adverse effect of the cancellation by sponsors of two large clinical studies in late 2016.
Major Factors: Per management, LabCorp made impressive progress and performed outstandingly in the Diagnostics business during the quarter. In the LabCorp Diagnostics business, the company had excellent revenue growth, with significant increases in both total and organic volume and revenue per requisition, leading to expansion of our industry-leading margins. The company has also updated its full year 2017 outlook.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session
Check back later for our full write up on this LabCorp earnings report later!
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
LabCorp (LH) Tops Q1 Earnings, Misses Revenue Estimate
Laboratory Corp. of America Holdings (LH - Free Report) is a leading independent clinical laboratory, whose offerings include a broad range of routine tests (including blood chemistry analysis, urinalyses, blood cell count, thyroid test, Pap tests and HIV tests) as well as specialty testing operations or esoteric testing.
Currently, LabCorp has a Zacks Rank #4(Sell) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at $2.19 per share over the last 30 days. LabCorp’s first quarter adjusted earnings per share of $2.22, up 8% year over year has surpassed this estimate by 1.4%.
Laboratory Corporation of America Holdings Price and EPS Surprise
Laboratory Corporation of America Holdings Price and EPS Surprise | Laboratory Corporation of America Holdings Quote
Sales: LabCorp posted sales of $2,408.1 million in the reported quarter, which has marginally missed the Zacks Consensus Estimate for sales of $2,411.0 million.
Key Stats: Revenues from LabCorp Diagnostics segment increased 8.0% year over year to $1.72 billion in the first quarter, with total volume growth of 4.3%. However, revenues from Covance Drug Development segment declined by 1.8% year over year to $690.3 million because of sluggish revenue conversion and adverse effect of the cancellation by sponsors of two large clinical studies in late 2016.
Major Factors: Per management, LabCorp made impressive progress and performed outstandingly in the Diagnostics business during the quarter. In the LabCorp Diagnostics business, the company had excellent revenue growth, with significant increases in both total and organic volume and revenue per requisition, leading to expansion of our industry-leading margins. The company has also updated its full year 2017 outlook.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session
Check back later for our full write up on this LabCorp earnings report later!